| Product Name |
Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Stabilized Trimer, United Kingdom Variant
|
| Description |
Lentivirus particles
pseudotyped with SARS-CoV-2
spike glycoprotein, with hexaPro mutations so the surface protein antigenically optimal pre-fusion conformation, produced and purified from HEK 293 cells. This pseudovirus has N501Y mutation.
|
| Mutations |
Furin site RRAR mutated to GSAS; HexaPro mutations (K986P, V987P, F817P, A892P, A899P and A942P) to ensure the S glycoprotein remains in an antigenically optimal pre-fusion conformation;
United Kingdom mutations: N501Y
|
Source
|
HEK293T cells
|
Reporter
|
EGFP
|
| Application |
- Screening of SARS-CoV-2
neutralizing antibodies
-
Assessment of vaccine efficacy
|
| Titer |
> 1 X 107 RFU/ml or > 1 X 105 TU/ml
|
| Shipping |
Dry ice |
| Storage |
-80 oC |
References
|
- Efective
screening of SARS-CoV-2
neutralizing antibodies in patient
serum using lentivirus particles
pseudotyped with SARS-CoV-2
spike glycoprotein. Sci Rep 10, 19076 (2020). doi:10.1038/s41598-020-76135-w
- Prospective Mapping of Viral Mutations that Escape
Antibodies Used to Treat COVID-19. Science. 371 (2020): 850-854. doi:
10.1126/science.abf9302. PubMed: 33495308.
|